Allergic Rhinitis
📧 Sign up to get email alerts when something new happens for Allergic Rhinitis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-06-07FDA Approved: MONTELUKAST — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for Montelukast submitted by BluePoint Laboratories.
-
FDA approval · 2023-06-07FDA Approved: RYALTRIS — Supplemental Application (HIKMA SPECIALTY USA INC.)
FDA approved a supplemental application for RYALTRIS (olopatadine hydrochloride and mometasone furoate) submitted by Hikma Specialty USA Inc…
-
EMA approval · 2023-06-01EMA Authorised: Desloratadine Actavis (desloratadine) — Actavis Group PTC ehf
The EMA has authorised Desloratadine Actavis (desloratadine) for allergic rhinitis and urticaria indications in the European Union.
-
FDA approval · 2023-05-31FDA Approved: CLARITIN LIQUI-GELS — Supplemental Application (Bayer HealthCare LLC.)
FDA approved a supplemental application for Claritin LiQui-Gels (loratadine). The new liquid-filled gel capsule formulation expands the Clar…
-
FDA approval · 2023-05-25FDA Approved: CLARITIN REDITABS — Supplemental Application (Bayer HealthCare LLC)
The FDA approved a supplemental application for Claritin RediTabs (loratadine) to introduce a new dosage form for Bayer HealthCare LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-05-24FDA Approved: RUGBY MOMETASONE FUROATE NASAL — Supplemental Application (Rugby Laboratories)
FDA approved a supplemental application for Rugby Mometasone Furoate Nasal spray from Rugby Laboratories (NDA 215712). The approval pertaine…
-
FDA approval · 2023-05-23FDA Approved: FEXOFENADINE HYDROCHLORIDE — Original Application (Aurohealth LLC)
FDA approves Aurohealth LLC's generic fexofenadine hydrochloride (oral) under Orig AP; indicated for allergic rhinitis and chronic idiopathi…
-
FDA label_change · 2023-05-10FDA Approved: METHYLPREDNISOLONE ACETATE — Supplemental Application (Sandoz Inc.)
FDA approved a supplemental application for methylprednisolone acetate by Sandoz Inc.
-
FDA approval · 2023-05-08FDA Approved: BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for the cough/cold combination of brompheniramine maleate, pseudoephedrine hydrochloride, and dextro…
-
FDA approval · 2023-05-01FDA Approved: DESLORATADINE — Supplemental Application (Virtus Pharmaceuticals, LLC)
FDA approved a supplemental application for desloratadine from Virtus Pharmaceuticals, LLC.
-
FDA approval · 2023-04-19FDA Approved: CETIRIZINE HYDROCHLORIDE ORAL SOLUTION — Supplemental Application (APOZEAL PHARMACEUTICALS INC)
FDA approved a supplemental application for cetirizine hydrochloride oral solution by Apozeal Pharmaceuticals, updating the approved labelin…
-
FDA approval · 2023-04-13FDA Approved: ALLERGY RELIEF — Supplemental Application (WALGREENS)
FDA approves Walgreens' supplemental application for an allergy-relief product containing cetirizine hydrochloride (Allergy Relief).
-
FDA approval · 2023-04-12FDA Approved: BUDESONIDE — Original Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved the original application for Budesonide from Padagis Israel Pharmaceuticals Ltd, granting a generic version of budesonide. The …
-
FDA approval · 2023-03-24FDA Approved: LORATADINE — Original Application (Aurohealth LLC)
The FDA approved Aurohealth LLC's original application for loratadine, a generic antihistamine. It covers indications for allergic rhinitis …
-
FDA approval · 2023-03-08FDA Approved: CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE — Original Application (Aurohealth LLC)
FDA approved Aurohealth LLC's cetirizine hydrochloride and pseudoephedrine hydrochloride as an original ANDA, enabling a generic combination…
-
FDA approval · 2023-02-28FDA Approved: PHENYLEPHRINE HYDROCHLORIDE — Original Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a generic version of phenylephrine hydrochloride through an Original Application (ANDA 209968) by Heritage Pharmaceuticals (d/b…
-
CLINICAL_TRIALS trial_result · 2023-02-01Clinical Trial Update: Safety and Efficacy Study of PA9159 Nasal Spray for the Treatment of Seasonal Allergic Rhinitis [Phase 2]
Phase 2 safety and efficacy study of PA9159 nasal spray for seasonal allergic rhinitis has been completed.
-
FDA approval · 2023-01-20FDA Approved: XHANCE — Supplemental Application (OptiNose US, Inc.)
FDA approves a supplemental New Drug Application for XHANCE (fluticasone propionate) by OptiNose US, Inc.
-
CLINICAL_TRIALS trial_result · 2023-01-05Clinical Trial Update: Effects of Second-generation Antihistamine Bepotastine on Cough Outcomes in Cough Patients With Allergic Rhinitis [Phase 4]
Phase 4 trial update evaluating the effects of the second-generation antihistamine bepotastine on cough outcomes in patients with allergic r…
-
FDA approval · 2022-12-27FDA Approved: CLARITIN CHEWABLE GRAPE AND BUBBLEGUM — Supplemental Application (Bayer HealthCare LLC.)
FDA approved a supplemental application to add a new chewable grape and bubblegum formulation of Claritin (loratadine) from Bayer HealthCare…
-
CLINICAL_TRIALS trial_result · 2022-12-23Clinical Trial Update: Fighting Climate Change: Urban Greennes, Active Mobility and Health Co-benefits. [Phase 4]
Phase 4 trial update on urban greenness and active mobility with health co-benefits for respiratory and allergic symptoms.
-
FDA approval · 2022-12-20FDA Approved: CHILDRENS ALLEGRA ALLERGY — Supplemental Application (Chattem, Inc.)
FDA approved a supplemental application for Children's Allegra Allergy (fexofenadine hydrochloride) to support labeling for pediatric use, e…
-
CLINICAL_TRIALS trial_result · 2022-12-20Clinical Trial Update: Serum MicroRNAs 223 and 146a in Allergic Rhinitis Patients as Biomarkers for Efficacy of Sublingual Immunotherapy [Phase 3]
Phase 3 trial investigating serum microRNAs 223 and 146a as biomarkers for efficacy of sublingual immunotherapy in allergic rhinitis; study …
-
FDA approval · 2022-12-08FDA Approved: LORATADINE ODT — Supplemental Application (Aurohealth LLC)
FDA approved a supplemental application for Loratadine ODT from Aurohealth LLC, updating the labeling for loratadine in an orally disintegra…
-
CLINICAL_TRIALS trial_result · 2022-11-25Clinical Trial Update: Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis [Phase 1, Phase 2]
Phase 1/2 trial investigating safety, tolerability, and preliminary efficacy of B244 in healthy volunteers and individuals with seasonal all…